Market Cap 194.98M
Revenue (ttm) 134.48M
Net Income (ttm) -38.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.96%
Debt to Equity Ratio 0.00
Volume 1,004,900
Avg Vol 777,048
Day's Range N/A - N/A
Shares Out 41.40M
Stochastic %K 29%
Beta 1.14
Analysts Hold
Price Target $8.79

Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 521 7830
Website: rxsight.com
Address:
100 Columbia, Aliso Viejo, United States
longtermvalue1
longtermvalue1 Jun. 13 at 9:00 PM
$RXST is this down because the parents are expiring?
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 11 at 12:17 PM
$RXST if I only knew how to daytrade.....
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 8 at 5:42 PM
$RXST this board is dead.....
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 3 at 10:02 PM
$RXST can anyone explain the after hours jumps? Is it just algorithms trading blindly?
0 · Reply
upupandgetpaid
upupandgetpaid Jun. 3 at 6:35 PM
$RXST If everything is red, nothing is red, right? Or is that magical thinking.....
0 · Reply
DrLukas19
DrLukas19 Jun. 3 at 6:20 PM
$RXST Just started position. Negative enterprise value with cash burn of about $5-8 million per quarter. $210 million of cash. Risk/reward here is great IMO
0 · Reply
upupandgetpaid
upupandgetpaid Jun. 2 at 2:12 PM
$RXST This stock is trading below it's cash value? That's kind of insulting....
1 · Reply
OPmoney
OPmoney May. 23 at 2:04 PM
$RXST PSA update after April 1st/2nd LALs - last adjustment should have matched 20/15 vision in both, however the left eye clarity is now much better than the right, but both diminished. Cause is said to be: posterior capsule opacification (PCO) — the cloudy “scar tissue” that can form behind any intraocular lens. Means there was NO first Lock-in on May 22nd. LAL sequence is: Adjustment (wait 48 hrs) → Adjustment (wait 48 hrs) →Lock‑in #1 (wait 48hrs)→ Lock‑in #2 → YAG (if needed) My doctor saying always/common to do YAG first, however doing YAG before lock‑ins? AI says is not typical, because the capsule helps keep the lens stable during the UV‑adjustment phase. However, must consider a lock‑in now could freeze in the wrong prescription, I'd end up with a permanent refractive error. So the doctor is choosing the option that preserves the accuracy of the final vision, even though it’s not the textbook sequence. I trust my doc. We'll see...... YAG is scheduled for mid-June.
1 · Reply
OPmoney
OPmoney May. 15 at 4:36 PM
$RXST PSA update after April 1st/2nd LALs - 5/14 was the second tweak @ .25 Astigmatism in Rt eye only. STILL seeing 20/15 in both eyes. Still wearing UV blocker dark sunglasses. Switched from iVIZIA Sterile Lubricant Eye Drops to Refresh Optive Advanced for Dry Eyes. Now there is no signs of any dry-eye. Using +2.75 readers for really close-up work and +1.75 for close desk/computer screens, and +1.25 for computers on desk at full arm's length. Lens-wise, no glare, no halos, right eye was best first then the Outline of lens in left eye noticed every morning is now gone too. BOTH eyes may have to deal with a final treatment (YAG laser) for scar tissue, said to be a floater creator...hope not. Otherwise - all clearer and brighter with next week set for first "lock-in"
0 · Reply
BryGuy29
BryGuy29 May. 7 at 2:01 PM
$RXST yikes. Great tech, but honestly, this company should be acquired by a bigger company to open the tech to more offices.
1 · Reply
Latest News on RXST
RxSight Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 1:00 PM EDT - 20 days ago

RxSight Transcript: Stifel 2026 Virtual Ophthalmology Forum


RxSight price target lowered to $11 from $13 at Needham

2026-05-07T13:37:20.000Z - 5 weeks ago

RxSight price target lowered to $11 from $13 at Needham


RxSight reports Q1 adjusted EPS (19c), consensus (15c)

2026-05-07T00:52:25.000Z - 5 weeks ago

RxSight reports Q1 adjusted EPS (19c), consensus (15c)


RxSight Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

RxSight Earnings Call Transcript: Q1 2026


RxSight Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

RxSight Earnings release: Q1 2026


RxSight Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

RxSight Quarterly report: Q1 2026


RxSight Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 5 weeks ago

RxSight Slides: Corporate presentation


RxSight Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

RxSight Proxy statement: Proxy filing


RxSight Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

RxSight Proxy statement: Proxy filing


RxSight price target lowered to $9 from $10 at Stifel

2026-03-09T11:16:16.000Z - 3 months ago

RxSight price target lowered to $9 from $10 at Stifel


RxSight price target lowered to $10 from $11 at Piper Sandler

2026-02-26T13:26:59.000Z - 3 months ago

RxSight price target lowered to $10 from $11 at Piper Sandler


RxSight price target raised to $9 from $8 at UBS

2026-02-26T13:15:33.000Z - 3 months ago

RxSight price target raised to $9 from $8 at UBS


RxSight reports Q4 EPS (3c), consensus (20c)

2026-02-25T21:49:05.000Z - 3 months ago

RxSight reports Q4 EPS (3c), consensus (20c)


RxSight sees FY26 revenue $120M-$135M, consensus $135.34M

2026-02-25T21:47:02.000Z - 3 months ago

RxSight sees FY26 revenue $120M-$135M, consensus $135.34M


RxSight Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

RxSight Earnings Call Transcript: Q4 2025


RxSight Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

RxSight Annual report: Q4 2025


RxSight Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

RxSight Earnings release: Q4 2025


RxSight initiated with a Market Perform at William Blair

2026-01-30T11:45:23.000Z - 4 months ago

RxSight initiated with a Market Perform at William Blair


RxSight price target raised to $11 from $10 at Piper Sandler

2026-01-20T11:52:30.000Z - 5 months ago

RxSight price target raised to $11 from $10 at Piper Sandler


RxSight Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 5 months ago

RxSight Slides: Corporate presentation


RxSight appoints Wilterding as CFO

2026-01-11T19:20:25.000Z - 5 months ago

RxSight appoints Wilterding as CFO


RxSight reports preliminary Q4 revenue $32.6M, consensus $27.5M

2026-01-11T19:20:19.000Z - 5 months ago

RxSight reports preliminary Q4 revenue $32.6M, consensus $27.5M


RxSight raises FY25 revenue guidance to $134.5M vs $125M-$130M

2026-01-11T19:20:10.000Z - 5 months ago

RxSight raises FY25 revenue guidance to $134.5M vs $125M-$130M


RxSight announces CFO transition

2025-12-22T22:25:21.000Z - 6 months ago

RxSight announces CFO transition


RxSight, Inc. Announces Chief Financial Officer Transition

Dec 22, 2025, 5:15 PM EST - 6 months ago

RxSight, Inc. Announces Chief Financial Officer Transition


RxSight price target raised to $10 from $9 at Morgan Stanley

2025-12-02T11:40:27.000Z - 6 months ago

RxSight price target raised to $10 from $9 at Morgan Stanley


RxSight price target raised to $10 from $8 at Stifel

2025-11-06T17:00:27.000Z - 7 months ago

RxSight price target raised to $10 from $8 at Stifel


RxSight price target raised to $9 from $8 at JPMorgan

2025-11-06T12:57:21.000Z - 7 months ago

RxSight price target raised to $9 from $8 at JPMorgan


RxSight Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

RxSight Earnings Call Transcript: Q3 2025


RxSight Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

RxSight Quarterly report: Q3 2025


RxSight Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 7 months ago

RxSight Earnings release: Q3 2025


RxSight, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 7 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results


RxSight Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

RxSight Earnings Call Transcript: Q2 2025


RxSight Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

RxSight Quarterly report: Q2 2025


RxSight Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

RxSight Earnings release: Q2 2025


RxSight, Inc. Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 11 months ago

RxSight, Inc. Reports Second Quarter 2025 Financial Results


longtermvalue1
longtermvalue1 Jun. 13 at 9:00 PM
$RXST is this down because the parents are expiring?
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 11 at 12:17 PM
$RXST if I only knew how to daytrade.....
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 8 at 5:42 PM
$RXST this board is dead.....
1 · Reply
upupandgetpaid
upupandgetpaid Jun. 3 at 10:02 PM
$RXST can anyone explain the after hours jumps? Is it just algorithms trading blindly?
0 · Reply
upupandgetpaid
upupandgetpaid Jun. 3 at 6:35 PM
$RXST If everything is red, nothing is red, right? Or is that magical thinking.....
0 · Reply
DrLukas19
DrLukas19 Jun. 3 at 6:20 PM
$RXST Just started position. Negative enterprise value with cash burn of about $5-8 million per quarter. $210 million of cash. Risk/reward here is great IMO
0 · Reply
upupandgetpaid
upupandgetpaid Jun. 2 at 2:12 PM
$RXST This stock is trading below it's cash value? That's kind of insulting....
1 · Reply
OPmoney
OPmoney May. 23 at 2:04 PM
$RXST PSA update after April 1st/2nd LALs - last adjustment should have matched 20/15 vision in both, however the left eye clarity is now much better than the right, but both diminished. Cause is said to be: posterior capsule opacification (PCO) — the cloudy “scar tissue” that can form behind any intraocular lens. Means there was NO first Lock-in on May 22nd. LAL sequence is: Adjustment (wait 48 hrs) → Adjustment (wait 48 hrs) →Lock‑in #1 (wait 48hrs)→ Lock‑in #2 → YAG (if needed) My doctor saying always/common to do YAG first, however doing YAG before lock‑ins? AI says is not typical, because the capsule helps keep the lens stable during the UV‑adjustment phase. However, must consider a lock‑in now could freeze in the wrong prescription, I'd end up with a permanent refractive error. So the doctor is choosing the option that preserves the accuracy of the final vision, even though it’s not the textbook sequence. I trust my doc. We'll see...... YAG is scheduled for mid-June.
1 · Reply
OPmoney
OPmoney May. 15 at 4:36 PM
$RXST PSA update after April 1st/2nd LALs - 5/14 was the second tweak @ .25 Astigmatism in Rt eye only. STILL seeing 20/15 in both eyes. Still wearing UV blocker dark sunglasses. Switched from iVIZIA Sterile Lubricant Eye Drops to Refresh Optive Advanced for Dry Eyes. Now there is no signs of any dry-eye. Using +2.75 readers for really close-up work and +1.75 for close desk/computer screens, and +1.25 for computers on desk at full arm's length. Lens-wise, no glare, no halos, right eye was best first then the Outline of lens in left eye noticed every morning is now gone too. BOTH eyes may have to deal with a final treatment (YAG laser) for scar tissue, said to be a floater creator...hope not. Otherwise - all clearer and brighter with next week set for first "lock-in"
0 · Reply
BryGuy29
BryGuy29 May. 7 at 2:01 PM
$RXST yikes. Great tech, but honestly, this company should be acquired by a bigger company to open the tech to more offices.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 8:10 PM
$RXST Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.38 down -90.00% YoY • Reported revenue of $30.89M down -18.48% YoY • RxSight expects to incur net operating losses and negative cash flows for the foreseeable future, despite anticipating revenue growth from expanded sales and marketing efforts, with current cash sufficient for at least 12 months.
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 6:39 PM
0 · Reply
OPmoney
OPmoney Apr. 23 at 6:02 PM
$RXST PSA update after 22 days Post-Op: 4/21 was 1st UV tweek to LALs - looking at seeing 20/15 in both eyes. Still wearing UV blocker dark sunglasses, iVIZIA Sterile Lubricant Eye Drops for Dry Eyes every hour or two, using +2.75 readers for close work and +1.25 for desk/computer screens. So far, so good, clearer and brighter - future so bright ...
1 · Reply
focafoca99
focafoca99 Apr. 8 at 10:21 PM
$RXST highlighted the milestone of 300,000 Light Adjustable Lens implants and a heavy scientific presence at ASCRS 2026.
0 · Reply
OPmoney
OPmoney Apr. 6 at 7:21 PM
$RXST PSA #1 from 2025: As far as posting up insight on another patient's own LAL experience Nov. 2023 in one eye. There is some improvement. Can see because cataract was removed, however doctor's recent reco, after a year of own blood Serum-eyedrops for severe dry eye is now try Oxervate $100K eye drops. As of 10-days ago cornea looks like "sand paper." Same thing was said after lock-in over a year ago. NO FUN, plus this patient also suffers from Trigeminal neuralgia - no pain- only numbness on same side of face as LAL since. While there is visual improvement since the cataract was removed, the road post "lock-in" has been complicated by chronic ocular surface issues: The "Sandpaper" Effect: A recent exam revealed the cornea still looks like "sandpaper." This is the same condition reported after the initial lock-in over a year ago. The battle with corneal health continues. It’s a reminder that even with the best lens technology, the "window" (the cornea) has to be clear for it to work.
1 · Reply
OPmoney
OPmoney Apr. 6 at 7:09 PM
$RXST PSA: After undergoing a vitrectomy in both eyes this past September, then earning early onset cataracts - I just spent 10K and am now the proud owner of RxSight Light Adjustable Lenses (LALs) in each eye. Here is the current status: Distance Vision: Five days post-op and things are looking pretty clear in both. AMAZING how clear and bright everything is. The Rx does not match. There is a glare line in dark, looking at lightbulb from 11 to 5 in left and 10 to 4 in right. Near Vision: Currently using +2.75 readers for typing and close work. Maintenance: On a regimen of eye drops 3x daily. UV Dark Glasses mandatory outdoors, not so much indoors. Next Steps: Follow-up appointment scheduled in 10 days. So far, so good! It’s quite an investment, but the progress is encouraging. Added one new "floater" in left eye and two in the right. 1st lock-in is weeks away. Feel free to DM with any questions or concerns.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:29 PM
$RXST to appear at the Needham Virtual Healthcare Conference on April 16.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 3:52 PM
$RXST Share Price: $6.33 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.34 – $5.30 Potential Upside: 62% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 23 at 10:46 AM
$RXST Rxsight inc. ✅️ BUY ZONE 6.41 to 6.35 ✋️ RISK BELOW 6.18 💲PT. 6.75 6.80 7.20 7.64 8.10 + Follow for more
0 · Reply